Henrik Jespersen

  • Consultant; PHD
 

Publications 2022

Jespersen H (2022)
Moles and melanoma
Tidsskr Nor Laegeforen, 142 (15)
DOI 10.4045/tidsskr.22.0626, PubMed 36286558

Publications 2021

Bjursten S, Pandita A, Zhao Z, Fröjd C, Ny L, Jensen C, Ullerstam T, Jespersen H, Borén J, Levin M, Zetterberg H, Rudin A, Levin M (2021)
Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis
J Immunother Cancer, 9 (7)
DOI 10.1136/jitc-2021-002732, PubMed 34215689

Jespersen H (2021)
[Reflection on ‘cure’]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0626, PubMed 34596998

Jespersen H (2021)
Reflection on curation
Tidsskr. Nor. Laegeforen., 141 (13), 1243

Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah VR, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA (2021)
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Nat Commun, 12 (1), 5155
DOI 10.1038/s41467-021-25332-w, PubMed 34453044

Sah VR, Karlsson J, Jespersen H, Lindberg MF, Nilsson LM, Ny L, Nilsson JA (2021)
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
Melanoma Res, 32 (4), 241-248
DOI 10.1097/CMR.0000000000000791, PubMed 34753889

Publications 2020

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA (2020)
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
Cell Death Dis, 11 (2), 99
DOI 10.1038/s41419-020-2301-y, PubMed 32029719

Holmberg CJ, Katsarelias D, Jespersen H, Carneiro A, Elander NO, Helgadottir H, Isaksson K, Jansson M, Wirén S, Ullenhag GJ, Ny L, Olofsson Bagge R (2020)
Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial
Acta Oncol, 60 (1), 52-55
DOI 10.1080/0284186X.2020.1846213, PubMed 33252282

Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindnér P, Larsson E, Olofsson Bagge R, Nilsson JA (2020)
Molecular profiling of driver events in metastatic uveal melanoma
Nat Commun, 11 (1), 1894
DOI 10.1038/s41467-020-15606-0, PubMed 32313009

Publications 2019

Arheden A, Skalenius J, Bjursten S, Stierner U, Ny L, Levin M, Jespersen H (2019)
Real-world data on PD-1 inhibitor therapy in metastatic melanoma
Acta Oncol, 58 (7), 962-966
DOI 10.1080/0284186X.2019.1620966, PubMed 31151362

Forsberg EMV, Lindberg MF, Jespersen H, Alsén S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA (2019)
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice
Cancer Res, 79 (5), 899-904
DOI 10.1158/0008-5472.CAN-18-3158, PubMed 30622115

Jespersen H, Olofsson Bagge R, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L (2019)
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
BMC Cancer, 19 (1), 415
DOI 10.1186/s12885-019-5623-3, PubMed 31046743

Publications 2018

Bagge RO, Demir A, Karlsson J, Alaei-Mahabadi B, Einarsdottir BO, Jespersen H, Lindberg MF, Muth A, Nilsson LM, Persson M, Svensson JB, Söderberg EMV, de Krijger RR, Nilsson O, Larsson E, Stenman G, Nilsson JA (2018)
Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary
JCO Precis Oncol, 2
DOI 10.1200/PO.18.00002, PubMed 32913988

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Olofsson Bagge R, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA (2018)
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
Cell Death Dis, 9 (8), 810
DOI 10.1038/s41419-018-0865-6, PubMed 30042422

Jespersen H, Bjursten S, Ny L, Levin M (2018)
Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases
Lancet Oncol, 19 (6), e327
DOI 10.1016/S1470-2045(18)30252-3, PubMed 29893264

Publications 2017

Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA (2017)
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Nat Commun, 8 (1), 707
DOI 10.1038/s41467-017-00786-z, PubMed 28955032

Publications 2014

Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA (2014)
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
Oncotarget, 5 (20), 9609-18
DOI 10.18632/oncotarget.2445, PubMed 25228592

Publications 2011

Jespersen H, Andersen JH, Ditzel HJ, Mouritsen OG (2011)
Lipids, curvature stress, and the action of lipid prodrugs: free fatty acids and lysolipid enhancement of drug transport across liposomal membranes
Biochimie, 94 (1), 2-10
DOI 10.1016/j.biochi.2011.07.029, PubMed 21839138

Publications 2010

Rasmussen N, Andersen JH, Jespersen H, Mouritsen OG, Ditzel HJ (2010)
Effect of free fatty acids and lysolipids on cellular uptake of doxorubicin in human breast cancer cell lines
Anticancer Drugs, 21 (7), 674-7
DOI 10.1097/CAD.0b013e32833c2cf7, PubMed 20559126

Page visits: 17